These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 23748277

  • 1. Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1.
    Giani M, Mastrangelo A, Villa R, Turolo S, Marra G, Tirelli AS, Hopfer H, Edefonti A.
    Pediatr Nephrol; 2013 Sep; 28(9):1837-42. PubMed ID: 23748277
    [Abstract] [Full Text] [Related]

  • 2. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 3. The effect of aldosterone blockade in patients with Alport syndrome.
    Kaito H, Nozu K, Iijima K, Nakanishi K, Yoshiya K, Kanda K, Przybyslaw Krol R, Yoshikawa N, Matsuo M.
    Pediatr Nephrol; 2006 Dec; 21(12):1824-9. PubMed ID: 17039334
    [Abstract] [Full Text] [Related]

  • 4. Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease.
    Guney I, Selcuk NY, Altintepe L, Atalay H, Başarali MK, Büyükbaş S.
    Ren Fail; 2009 Dec; 31(9):779-84. PubMed ID: 19925284
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-beta, and nitrite excretion.
    Adler L, Mathew R, Futterweit S, Frank R, Gauthier BG, Kashtan CE, Trachtman H.
    BMC Nephrol; 2002 Feb 14; 3():2. PubMed ID: 11869456
    [Abstract] [Full Text] [Related]

  • 6. Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria.
    Kim HY, Bae EH, Ma SK, Kim SW.
    Kidney Blood Press Res; 2014 Feb 14; 39(6):573-80. PubMed ID: 25531940
    [Abstract] [Full Text] [Related]

  • 7. Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome.
    Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, McCrary Sisk C, Lam C.
    Pediatr Nephrol; 2013 May 14; 28(5):737-43. PubMed ID: 23207876
    [Abstract] [Full Text] [Related]

  • 8. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
    Morales E, Gutiérrez E, Caro J, Sevillano A, Rojas-Rivera J, Praga M.
    Nefrologia; 2015 May 14; 35(6):554-61. PubMed ID: 26519114
    [Abstract] [Full Text] [Related]

  • 9. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF.
    Cochrane Database Syst Rev; 2014 Apr 29; (4):CD007004. PubMed ID: 24782282
    [Abstract] [Full Text] [Related]

  • 10. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.
    Bianchi S, Bigazzi R, Campese VM.
    Am J Kidney Dis; 2005 Jul 29; 46(1):45-51. PubMed ID: 15983956
    [Abstract] [Full Text] [Related]

  • 11. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
    Agarwal R, Siva S, Dunn SR, Sharma K.
    Am J Kidney Dis; 2002 Mar 29; 39(3):486-92. PubMed ID: 11877567
    [Abstract] [Full Text] [Related]

  • 12. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH, Lee SW, Suh JH, Kim ES, Hong SB, Kim KA, Kim MJ.
    Clin Nephrol; 2003 Nov 29; 60(5):318-26. PubMed ID: 14640237
    [Abstract] [Full Text] [Related]

  • 13. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.
    Am J Kidney Dis; 2008 Sep 29; 52(3):486-93. PubMed ID: 18423812
    [Abstract] [Full Text] [Related]

  • 14. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats.
    Han KH, Kang YS, Han SY, Jee YH, Lee MH, Han JY, Kim HK, Kim YS, Cha DR.
    Kidney Int; 2006 Jul 29; 70(1):111-20. PubMed ID: 16723984
    [Abstract] [Full Text] [Related]

  • 15. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
    Esteghamati A, Noshad S, Jarrah S, Mousavizadeh M, Khoee SH, Nakhjavani M.
    Nephrol Dial Transplant; 2013 Nov 29; 28(11):2823-33. PubMed ID: 24009294
    [Abstract] [Full Text] [Related]

  • 16. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
    Sato A, Suzuki Y, Saruta T.
    Hypertens Res; 1999 Mar 29; 22(1):17-22. PubMed ID: 10221346
    [Abstract] [Full Text] [Related]

  • 17. Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome.
    Zhang Y, Wang F, Ding J, Zhang H, Liu X, Wang S, Xiao H, Yao Y, Liu J, Zhong X, Guan N, Su B, Wu G, Yu L.
    Pediatr Nephrol; 2016 Jan 29; 31(1):67-72. PubMed ID: 26248473
    [Abstract] [Full Text] [Related]

  • 18. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.
    Bianchi S, Bigazzi R, Campese VM.
    Kidney Int; 2006 Dec 29; 70(12):2116-23. PubMed ID: 17035949
    [Abstract] [Full Text] [Related]

  • 19. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
    Kang YS, Ko GJ, Lee MH, Song HK, Han SY, Han KH, Kim HK, Han JY, Cha DR.
    Nephrol Dial Transplant; 2009 Jan 29; 24(1):73-84. PubMed ID: 18682491
    [Abstract] [Full Text] [Related]

  • 20. [The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ].
    Morales E, Huerta A, Gutiérrez E, Gutiérrez Solís E, Segura J, Praga M.
    Nefrologia; 2009 Jan 29; 29(5):421-9. PubMed ID: 19820754
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.